New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
09:59 EDTPAY, THR, MIND, KMB, GNW, ESV, DTV, DB, CHA, CTL, AZN, ARCP, MO, ATKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Neutral from Buy at Goldman... Altria Group (MO) downgraded to Market Perform from Outperform at Wells Fargo... American Realty (ARCP) downgraded to Neutral from Outperform at RW Baird... AstraZeneca (AZN) downgraded to Market Perform from Outperform at Leerink... CenturyLink (CTL) downgraded to Equal Weight from Overweight at Morgan Stanley... China Telecom (CHA) downgraded to Neutral from Buy at Goldman... Deutsche Bank (DB) downgraded to Underperform from Neutral at BofA/Merrill... DirecTV (DTV) downgraded to Hold from Buy at Wunderlich... Ensco (ESV) downgraded to Hold from Buy at Jefferies... Genworth (GNW) downgraded to Underweight from Equal Weight at Morgan Stanley... Kimberly Clark (KMB) downgraded to Hold from Buy at Argus... Mitcham Industries (MIND) downgraded to Accumulate from Buy at Global Hunter... Thermon Group (THR) downgraded to Hold from Buy at KeyBanc... VeriFone (PAY) downgraded to Neutral from Positive at Susquehanna.
News For ATK;MO;ARCP;AZN;CTL;CHA;DB;DTV;ESV;GNW;KMB;MIND;THR;PAY From The Last 14 Days
Check below for free stories on ATK;MO;ARCP;AZN;CTL;CHA;DB;DTV;ESV;GNW;KMB;MIND;THR;PAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 18, 2014
06:39 EDTDBEuropean banks take out EUR83B of loans from central bank, NY Times says
European banks agreed to take out EUR83B in low interest loans from the European Central Bank, as part of a program in which all of the funds must be loaned to businesses or individuals, or repaid to the central bank within two years, according to The New York Times. Several analysts had said that they would be disappointed if banks took out less than EUR100B in loans, but a number of analysts said that a second round of the program, due to occur in December after stress tests have been completed, may be more popular, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
September 17, 2014
15:50 EDTDTVDISH, DirecTV support committee passage of STAVRA legislation
DIRECTV (DTV) and DISH (DISH) issued the following statement regarding the passage of the Satellite Television Access and Viewer Rights Act, or STAVRA, out of the Senate Committee on Commerce, Science, & Transportation: "We thank Chairman Rockefeller, Ranking Member Thune and the rest of the Senate Commerce Committee for passing bipartisan legislation that makes important reforms to the outdated laws governing today’s video market, while ensuring continuity of service to more than 1.5M distant signal subscribers who would, otherwise, lose service at the end of this year. We look forward to working with Congressional leadership to see this reauthorization swiftly passed into law, and also look forward to continuing the important discussion regarding retransmission consent reform, and in particular protecting consumers from local channel blackouts.”
13:34 EDTDTVAT&T could need significant debt to pursue America Movil assets, WSJ says
Subscribe for More Information
10:13 EDTCTLRackspace sinks after deciding to remain independent
Subscribe for More Information
08:02 EDTPAYVeriFone expands Point-to-Point Encryption services to UK
Subscribe for More Information
07:43 EDTAZNBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
14:44 EDTDBVirginia AG files $1.15B lawsuit against banks that sold RMBS during crisis
Subscribe for More Information
14:33 EDTAZNNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
12:37 EDTAZNNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
11:51 EDTAZNOECD looks to close tax loopholes with new proposals
Subscribe for More Information
10:52 EDTCHAApple, China Mobile trade lower as iPhone 6 unlikely to debut in China this year
Subscribe for More Information
10:19 EDTAZNFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
09:25 EDTCHAOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTCHAApple may need to wait until 2015 to launch iPhone 6 in China, Bloomberg says
Subscribe for More Information
08:37 EDTKMBKimberly Clark subsidiary begins raising external financing
Subscribe for More Information
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:49 EDTMOBofA/Merrill to hold a conference
Subscribe for More Information
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use